1. Scrip
  2. >>R&D
  3. >>Clinical Trials

RAINFALLs On Lilly's Cyramza Stomach Cancer Parade

 
• By Alexandra Shimmings

A lack of overall survival benefit in first-line stomach cancer in a Phase III trial has scuppered Eli Lilly's hopes of expanding Cyramza's use into a new and relatively empty market.

Raindrops
Rainy days for Lilly's Cyramza plans • Source: Shutterstock

Eli Lilly & Co.'s VEGF inhibitor Cyramza (ramucirumab) has failed to improve overall survival when used first line in stomach cancer, top-line data from the RAINFALL study show. The company has dropped plans to file for a supplemental approval in what could have been a lucrative expanded indication where there is limited competition.

Lilly said that while the 645-patient study met its primary endpoint of progression-free survival, it did not provide a benefit...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Cidara’s Fortunes Improve Quickly With Non-Vaccine Flu-Prevention Data

 
• By Joseph Haas

Having recently abandoned the antifungal space, Cidara’s stock soared on Phase IIb data showing that its drug-Fc conjugate prevents seasonal flu at rates from 57%-76%.

Exelixis Positions Zanzalintinib For Post-Cabozantinib LOE Future

 
• By Alaric DeArment

The company announced positive Phase III data in previously treated colorectal cancer for zanzalintinib and it could see sales of more than $1bn in that indication.

Merck & Co.’s Winrevair Positioned For Expansion On HYPERION Results

 
• By Jessica Merrill

The Phase III trial met the primary endpoint of time to clinical worsening in patients newly diagnosed with pulmonary arterial hypertension.

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

More from R&D

Novo And Lilly Lay Out Patient Segmentation Plans For Obesity Treatment

 
• By Andrew McConaghie

As competition heats up and the obesity market matures, the two frontrunners are tailoring their studies to the wants and needs of different patient groups.

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.